Compendia Bioscience said this week that H3 Biomedicine has signed a three-year licensing agreement to use Compendia's Oncomine tool suite, which includes Oncomine Concepts and Oncomine Power Tools.
Furthermore, under the terms of the deal, the two companies will work together to mine data from the Cancer Genome Atlas in the hopes of discovering novel therapeutic targets and biomarkers to support drug development, Compendia said.
The financial details of the arrangement have not been disclosed.